The DPP-4 inhibitors have become a standard of care for the management of type 2 diabetes, frequently used as a second-line treatment after metformin failure or first-line treatment in those patients who are intolerant to metformin. Vildagliptin was one of the first DPP-4 inhibitors, and 2017 marked 10 years since its launch. The following publications explore the role of vildagliptin in type 2 diabetes management and discuss the clinical and real-world data that are now available.
Professor Stefano Del Prato outlines how DPP-4 inhibitors function and introduces the VERIFY and INTERVAL trials that are exploring the use of vildagliptin in early diagnosed- and elderly patients respectively.Read more
This review explores the discovery and clinical development of vildagliptin over the past 25 years.Read more
Over the past decade, DPP-4 inhibitors have significantly changed the type 2 diabetes treatment paradigm, with a shift in focus to treating the underlying pathophysiology of the condition. This review explores the changing diabetes landscape and rise of different patient populations and the implications this has on management and health economics.Read more
Vildagliptin has been extensively studied over the years. This review looks at the cumulative evidence for the safety and tolerability of vildagliptin from clinical development to real-world data.Read more